Medical Pharmacology Chapter 33-34:  Anticancer Drugs

Previous Page Next Page

Section Table of Contents

Site Table of Contents

Previous Page Next Page

Section Table of Contents

Site Table of Contents

References
  1. Wellstein A Giaccone G Atkins MB Sausville Chapter 66:  Cytotoxic Drugs in Goodman & Gilman's:  The Pharmacological Basis of Therapeutics, 13e, Brunton LL Hilal-Dandan R Knollmann BC, eds) 2018.

  2. Sausville EA Longo DL Chapter 103e Principles of Cancer Treatment, in Harrison's Online   (Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo,  J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015.

  3. Chu E  Cancer Chemotherapy Chapter 54 in Basic & Clinical Pharmacology, 14 e (Katzung BG The McGraw-Hill Companies, 2018 (on-line edition)

  4. Tew KD Chapter 17:  Alkylating Agents  in Principles & Practice of Oncology (DeVita, JR VT Lawrence TS Rosenberg SA, eds) 10e Wolters Kluwer Health 2015.

  5. Collins JM Cancer Pharmacology Chapter 29 in Abeloff's Clinical Oncology (Niederhuber JE Armitage JO Doroshow JH Kastan MB Tepper JE, eds)  5e Elsevier Churchill Livingstone, Philadelphia, PA 2014.

  6. Wellstein A Giaccone G Atkins MB Sausville Chapter 67:  Pathway-Targeted Therapies:  Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules in Goodman & Gilman's:  The Pharmacological Basis of Therapeutics, 13e, Brunton LL Hilal-Dandan R Knollmann BC, eds) 2018.

  7. Thomas A Do K Kummar S Doroshow JH Pommier Y Chapter 23:  Topoisomerase-Interacting Agents  in DeVita, JR VT Lawrence TS Rosenberg SA, eds) 11e Wolters Kluwer Health 2018.

  8. Thomas A Pommier Y Chapter 14 Topoisomerase Inhibitors in:  Cancer Chemotherapy, Immunotherapy and Biotherapy Principles and Practice Chabner BA Longo DL, eds 6e Wolters Kluwer 2019.

  9. Idarubicin: Drug Monographs, Access Medicine, Wolters Kluwer Clinical Drug Information, 2019.

  10. Williams ME (Summary and Comment | Oncology and Hematology) Which Anthracycline for AML Induction Therapy? NEJM Journal Watch September 8, 2017  https://www.jwatch.org/na44993/2017/09/08/which-anthracycline-aml-induction-therapy [review of Lee JH Kim J Joo Y Lee W Bae S Zang D Kwon J Kim M Lee J Lee G Lee J Choi Y Kim D Hur E Lim S Lee S Ryoo H Kim H Hyun M Lee K, Cooperative Study Group A for Hematology Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicine in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia J Clin Oncol 35(24):  2754-2763 Aug 20 2017; https://www.ncbi.nlm.nih.gov/pubmed/28632487]

  11. Robert J Clinical pharmacokinetics of idarubicin Clin Pharmacokinet 24(4):  275-288 Apr 1993. https://www.ncbi.nlm.nih.gov/pubmed/8491056

  12. Campana D Pui C-H Chilhood Leukemia Chapter 96 in Abeloff's Clinical Oncology (Niederhuber JE Armitage JO Doroshow JH Kastan MB Tepper JE, eds)  5e Elsevier Churchill Livingstone, Philadelphia, PA 2014.

  13. Hijiya N Ness K Ribeiro R Hudson M Acute Leukemia as a Secondary Malignancy in Children and Adolescents:  Current Findings and Issues Cancer 115(1):  23-25 Jan 1, 2009 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767267/

  14. Ravandi F Nivolumab with cytarabine & idarubicin in newly diagnosed AML. https://www.youtube.com/watch?v=RKJKKE16hwo

  15. Valrubicin: Drug Monographs, Access Medicine, Wolters Kluwer Clinical Drug Information, 2019.

  16. Lerner S BCG Unresponsive Disease:  A Roadmap for Drug Development and Novel Therapies. https://www.youtube.com/watch?v=sPKenDA-QW8

This Web-based pharmacology teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.